Results 241 to 250 of about 2,351,070 (299)

Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial. [PDF]

Trials
Azizi F, Amouzegar A, Abdi H, Tohidi M, Masoumi S, Khalili D, Mehrabi Y, Zadehvakili A, Hedayati M, Momenan AA, Mehran L.   +10 more
europepmc   +1 more source

Effect of Slow-Release Urea on Yield and Quality of <i>Euryale ferox</i>. [PDF]

Int J Mol Sci
Wu P, Wang TY, Wang YH, Liu AL, Zhao SP, Feng K, Li LJ.   +6 more
europepmc   +1 more source

Slow-Release Pharmaceutical Implants in Ecotoxicology: Validating Functionality across Exposure Scenarios. [PDF]

ACS Environ Au
Bertram MG, Brand JA, Thoré ESJ, Cerveny D, McCallum ES, Michelangeli M, Martin JM, Fick J, Brodin T.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Slow-Release Fluoride

Caries Research, 2009
The latest evidence supports the concept of frequent applications of relatively low concentrations of fluoride for the elimination of caries, even in situations of high caries challenge. Dental materials exhibit a ‘burst effect’, and the fluoride release is short-lived.
K J, Toumba, M E, Curzon
openaire   +2 more sources

The pharmacokinetics of slow-release procainamide

European Journal of Clinical Pharmacology, 1978
Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0
W J, Tilstone, D H, Lawson, W, Campbell, I, Hutton, T D, Lawrie   +4 more
openaire   +2 more sources

Slow-release melarsoprol microparticles

International Journal of Pharmaceutics, 2002
The present study compares two methods of preparation of microparticles of melarsoprol for the treatment of the human trypanosomiasis. Melarsoprol is poorly soluble in water and in organic media. Microparticles were formulated with modified O/W and W/O/W methods, Poly(epsilon -caprolactone) microparticles were prepared either with a suspension-in-oil ...
Gibaud, Stéphane, Gaia, Adela, Astier, Alain   +2 more
openaire   +3 more sources

Nocturnal asthma: slow-release terbutaline versus slow-release theophylline therapy

European Respiratory Journal, 1988
In a double-blind cross-over study, the effects of slow release (S-R) terbutaline tablets (b.i.d. 0.25 mg/kg per day) and S-R theophylline (5.31 mg/kg morning and 10.62 mg/kg evening) were compared in eleven patients with nocturnal asthma. On day seven of each treatment period, drug serum concentrations and peak expiratory flow (PEF) were measured ...
M, Heins, L, Kurtin, M, Oellerich, R, Maes, G W, Sybrecht   +4 more
openaire   +2 more sources

Cardiac Effects of Slow-Release Lanreotide, a Slow-Release Somatostatin Analog, in Acromegalic Patients

Journal of Clinical Endocrinology & Metabolism, 1999
Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-
BALDELLI R, FERRETTI, ELISABETTA, JAFFRAIN REA ML, IACOBELLIS G, MINNITI G, CARACCIOLO B, MORONI, Carlo, CASSONE, Rosario, GULINO, Alberto, TAMBURRANO, Guido   +9 more
openaire   +5 more sources

Preparation of Indapamide slow-release pellets

Advances in Therapy, 2004
During the process of developing a slow-release formulation of indapamide, researchers created a drug-containing pellet coated with Eudragit RS100 (Rohm GMbH & Co. KG, Darmstadt, Germany) to control the rate at which the drug was released. The two main variables were the agglomerants used in the pellet preparation and the amount of Eudragit RS100 used ...
Wei, Jia, Mingfeng, Qiu, Xia, Sun, Yungping, Qiu, Mingming, Su   +4 more
openaire   +2 more sources

Slow-Release Trihexyphenidyl in Parkinson's Disease

JAMA, 1962
TBIHEXYPHENIDYL (Ariane) hydrochloride was introduced as a synthetic drug for the treatment of Parkinson's disease by Drs. Doshay and Constable in August, 1949. It has proved to be one of the more useful drugs in the treatment of Parkinson's disease, and has been available in 2 mg. and 5 mg. scored tablets for the past 12 years.
R S, SCHWAB, L J, DOSHAY
openaire   +2 more sources